Gilead’s Lenacapavir On The Move Again As FDA Lifts Clinical Hold
The long-acting HIV drug’s greatest potential is for pre-exposure prophylaxis, where it would compete against ViiV’s long-acting injectable Apretude.
You may also be interested in...
The company said screening and diagnosis were still below pre-pandemic levels, but Biktarvy and Descovy brought HIV sales back into positive territory.
A long-acting injectable formulation of cabotegravir, Apretude could result in greater patient adherence to therapy, ViiV claims. The product will be priced at $3,700 per vial.
The partners are halting recruitment out of “an abundance of caution,” but Gilead could decide to exit the alliance if islatravir cannot shake off safety concerns.